CD4≤499 group. Instead of any health decrement associated with higher CD4 this was due to individual variability and reflects other forms of morbidity. The 350≤ CD4≤499 weight was therefore used for all children with CD4%≥16.
Note: Missing data was low. For the monitoring randomization, missing data was 9.2% of total 6-monthly observations for resource use, of which 6.5% is for the final costing period (weeks 208-228); and 12.6% for CD4%s, of which 7.5% is for the final period;
Key: rxmoncost*, CD4cost*,toxcost*, rxmonutil* -all costs, CD4 costs, toxicity test costs, utilities; associated with monitoring strategies ordered by 6 month periods from randomization. rxcotox_cst*, rxutil* -all costs, utilities associated with cotrimoxazole strategies ordered by 6 month periods from randomization. CDM n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 CDM n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 , the value of implementation activities to support the implementation of a cost-effective health care intervention can be determined as follows:
It is useful to have an estimate of the incremental cost per unit of health (e.g. QALY, life year gained) from one health care intervention compared to another clinically relevant and mutually exclusive alternative is called its cost-effectiveness ratio, or ICER. The calculation for an ICER is shown in 1 below:
1.
Where C A represents the costs associated with the more expensive health care intervention, C B the costs associated with the less expensive intervention, H A the QALYs with the more expensive intervention, and H B the QALYs with the less expensive intervention.
The value of the more expensive intervention (A), assuming it generates more health (QALYs), measured in terms of its ICER, is then compared to a cost-effectiveness threshold (k). The threshold represents the value of health gains foregone due to the resources subsequently being unavailable for other interventions after being committed to funding intervention A. Intervention A is therefore cost-effective if:
2.
An alternative but equivalent decision rule is present cost-effectiveness on a monetary scale using the measure of net monetary benefit (NMB), by which an intervention is cost-effective if NMB is greater than zero. The NMB statistics is shown in 3 below:
( ) ( )
NMB represents the net gain to a health system in terms of money from the introduction of the health intervention A. It captures the gains directly from the intervention and compares it to interventions foregone or gained elsewhere within the health system as a result of any cost differences with clinically relevant comparators (represented here as intervention B).
